compare retatrutide and tirzepatide vs — What to Know Before You Decide Retatrutide vs Tirzepatide: Triple vs

As emerging evidence builds, providers must balance potential benefits with safety concerns and patient-specific factors

Tirzepatide's Dual-Receptor Profile Tirzepatide was engineered as a GIP/GLP-1 co-agonist

Acknowledgements This work was supported in part by a National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) (R01 #HL155718-01) grant, and an American Foundation for Pharmaceutical Education (AFPE) Gateway to Research award (both to A.L.)

Accessed 09 July 2025 [cited]

Its maker Lilly could only make the pricing announcement following the completion of a phase 3 trial that confirms the efficacy results of the previous studies, as well as its safety profile

[11] [12] There is a potential risk of pancreatitis